You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,869,634


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,869,634
Title: Method of making an RNA particle for use in cleaving nucleic acid molecules and inserting a nucleic acid molecule into the cleavage site
Abstract:The present invention provides new methods, employing a nucleotide integrase, for cleaving double-stranded and single stranded DNA substrates at specific sites and for attaching nucleic acid molecules to the cleaved DNA substrates. One method uses a nucleotide integrase to cleave one strand of a double-stranded DNA and to concomitantly attach a nucleic acid molecule to the cleaved strand. Another method uses a nucleotide integrase to cleave both strands of a double-stranded DNA substrate and to attach a nucleic acid molecule to one strand of the DNA substrate. Another method uses a nucleotide integrase to cleave both strands of a double-stranded DNA substrate and to attach an RNA molecule to one strand of the substrate and for attaching a cDNA to the other strand of the substrate. Another method cleaves single stranded DNA with the concomitant insertion of a nucleic acid molecule at the cleavage point. The nucleotide integrase comprises an RNP particle which comprises a group II intron RNA bound to a group II intron encoded protein. The present invention also relates to purified and reconstituted RNP particles and reconstituted RNP that cleave DNA substrates.
Inventor(s): Lambowitz; Alan M. (Columbus, OH), Zimmerly; Steven (Columbus, OH), Yang; Jian (Columbus, OH), Guo; Huatao (Columbus, OH)
Assignee: The Ohio State Research Foundation (Columbus, OH)
Application Number:08/946,617
Patent Claims:1. A method for making a reconstituted RNP particle preparation comprising the following steps:

(a) providing an exogenous first RNA molecule which comprises an excised group II intron RNA and lacks flanking exon sequences, said group II intron RNA comprising a hybridizing region which is capable of hybridizing to a recognition site on a DNA substrate;

(b) providing an RNA-protein complex comprising:

(i) a protein having an amino acid sequence encoded by a group II intron, said protein comprising an X domain and a Zn domain, and

(ii) a second RNA molecule; wherein said second RNA molecule is not an excised group II intron RNA having a sequence that encodes said protein; and wherein said second RNA molecule is bound to said protein to form said RNA-protein complex; and

(c) combining said exogenous first RNA with said RNA-protein complex to form a reconstituted RNP particle that is capable of cleaving said DNA substrate, said reconstituted RNP particle comprising said first exogenous RNA molecule bound to said protein.

2. The method of claim 1 wherein the exogenous RNA comprises a yeast mitochondrial group II intron RNA and the protein comprises an amino acid sequence encoded by a yeast mitochondrial group II intron.

3. The method of claim 1 wherein the exogenous RNA comprises an excised RNA transcript that is encoded by the group II intron aI2 of the yeast mitochondrial COX1 gene and said protein comprises an amino acid sequence encoded by the group II intron aI2 of the yeast mitochondrial COX1 gene.

Details for Patent 5,869,634

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2015-09-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2015-09-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2015-09-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.